Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Alfa Cytology is pioneering the development of microbiota biomarkers for breast cancer diagnostics, striving to provide accurate, reliable, and personalized diagnostic solutions.
Breast cancer (BC) is the most common malignancy in women worldwide, and early diagnosis and appropriate treatment of BC can improve survival chances. The milk secreted by the breast tissue joins the nipple through ducts at all levels and opens to the outside world. Therefore, the human breast is not sterile and contains a unique and diverse bacterial flora structure. Recent studies have shown that BC can be positively or negatively affected by the local mammary microbiota or gut microbiota. The microbiota can increase/decrease breast cancer risk by modulating circulating steroid hormone levels, modulating energy intake and utilization, synthesizing metabolites such as genotoxins, lipopolysaccharides, vitamins, and antibiotics, and modulating the immune system. Therefore, the microbiota can serve as a biomarker for breast cancer diagnosis.
Fig.1 Microbiome and regulation of estrogen in breast cancer. (Viswanathan S, et al., 2023)
Alfa Cytology is a leading preclinical CRO company with extensive experience in BC basic research and biomarkers development. With advanced technology and a professional team, we can provide BC diagnostic development services, including microbiome biomarkers development for BC diagnostics. As an important part of the body, the microbiota has been considered an important mediator in regulating tumor susceptibility and disease progression in recent years. The microbiota in the mammary gland and intestinal tract are related to the occurrence and development of BC. The mechanism of action may include changing the barrier function, affecting the level of estrogen and lipid metabolism, chronic inflammation and immune regulation, DNA damage, and other potential pathways. We have professional microbial detection platforms,
For the development of BC diagnostic biomarkers, we focus on tumor microbiota and gut microbiota, our services include,
Alfa Cytology has extensive experience in biomarker development. Microbiota in breast tissue and gut vary by race, stage, and breast tumor subtype and are associated with cancer initiation, progression, and prognosis. It is a very promising research direction to dig deeper into the mechanism of microbial action in BC and search for new biomarkers. Our service is dedicated to contributing to the discovery of BC biomarkers and emphasizing the critical role of microbiota in BC monitoring. If you are interested in learning more about our BC diagnostic development services, please feel free to contact us. Our professional and patient staff will get in touch with you as soon as possible.
Reference